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Serial passage of an initially avirulent influenza B virus, B/Memphis/12/97, resulted in the selection of a variant which was lethal in mice.
Virulence correlated with improved growth in vivo and prolonged replication. Sequencing of the complete coding regions of the parent and
mouse-adapted viruses revealed 8 amino acid differences. Sequencing and characterization of intermediate passages suggested that one
change in the C-terminal domain of the M1 protein, an asparagine to a serine at position 221, was responsible for acquisition of virulence and
lethality. Site-directed mutagenesis of the M segment of a different virus, B/Yamanashi/166/98, to change this amino acid residue confirmed
its importance by conferring improved growth and virulence in mice. This observation suggests a role for the C domain of the M1 protein in
growth and virulence in a mammalian host.
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Three types of influenza viruses exist, termed influenza A,
B, and C viruses (Nicholson, 1998). Although both influenza
A and B viruses are important in human disease, there are
differences in their evolution and epidemiology (McCullers et
al., 1999a, 1999b; Yamashita et al., 1988). InfluenzaAviruses
evolve by periodic antigenic shift taking genes from a large
avian reservoir (Webster et al., 1992), as well as by constant
antigenic drift (Fitch et al., 1991; Webster et al., 1982) and
reassortment among circulating human strains (Lindstrom et
al., 1998). Influenza B viruses also undergo antigenic drift
(Air et al., 1990; Krystal et al., 1983; McCullers et al., 2004)
and reassortment (Lindstrom et al., 1999; McCullers et al.,
1999b, 2004) but do not have a non-human gene pool from
which antigenic shift might occur. While the pandemic
potential of influenza Aviruses has made them natural targets
for study, influenza B viruses have received less attention.
One of the challenges facing such study is the lack of a good0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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pathogens of mice, and the few mouse-adapted viruses
available were generated by passage through animals such
as ferrets and mice rather than by culture in eggs or tissue
(Francis, 1940) and are only distantly related to the strains
circulating today. There is interest in small animal vaccine
challenge and drug treatment models for influenza B viruses.
Mouse adaptation of a modern strain, identification of the
responsible amino acid changes, and application of reverse
genetics techniques to introduce these changes into other
viruses should allow better study of these viruses.
Mouse adaptation and the acquisition of virulence by
passage in mouse lungs have been studied in influenza A
viruses and is a pleiotropic process (Brown, 1990; Brown et
al., 2001; Gitelman et al., 1984; Govorkova et al., 2000;
Hartley et al., 1997; Scheiblauer et al., 1995; Smirnov et al.,
2000;Ward, 1995, 1997). Multiple gene changes occur, and it
is unclear which are responsible for either adaptation or
virulence. Most studies have focused on changes in either the
hemagglutinin (HA) (Brown, 1990; Frosner and Gerth, 1973;
Gitelman et al., 1984; Govorkova et al., 2000; Hartley et al.,
1997; Kaverin et al., 1989; Rudneva et al., 1986; Smeenk and05) 318 – 326
J.A. McCullers et al. / Virology 336 (2005) 318–326 319Brown, 1994; Smeenk et al., 1996; Smirnov et al., 2000) or
thematrix (M1) (Govorkova et al., 2000; Smeenk and Brown,
1994; Smeenk et al., 1996; Ward, 1995) genes as determining
factors. After successfully mouse adapting an influenza B
virus, we wanted to determine the gene(s) responsible and
compare our findings to published studies on influenza A
virus. We expected to reap two benefits from these studies,
obtaining targets for understanding the role of particular
genes in the manifestation of disease, and identification of
specific amino acids which might be altered by reverse
genetics (Hoffmann et al., 2002) to confer mouse adaptation
and/or virulence on influenza B viruses. We report here that a
single amino acid change in the M1 gene of an influenza B
virus conferred virulence and lethality during the adaptation
process.Fig. 1. Growth of mouse-adapted intermediates in MDCK cell culture. Viral
titer was assayed at 96 h (A) for parental virus (M0), 3rd (M3), 6th (M6),
9th (M9), and 15th (MA, mouse adapted) passages. Time course of
infection (B) was assayed by measuring the HA titer of the viruses in
MDCK supernatants at intervals following infection and is expressed as the
log2 reciprocal titer. No significant differences in viral growth characte-
ristics were observed in tissue culture.Results
Growth characteristics of mouse-adapted intermediates
Influenza virus B/Memphis/12/97 (Mem97) was passaged
15 times through mouse lungs until it was lethal in mice.
Virus was amplified in MDCK cells between each lung
passage, resulting in 15 initial virus stocks. Five viruses were
selected for study, the parent virus Mem97 (M0), 3 inter-
mediate passages (M3, M6, M9), and the 15th passage (MA).
After plaque purification and preparation of virus stocks
under identical conditions, we determined the growth
characteristics of the viruses in MDCK cells. No significant
differences could be observed in the peak viral titers of the
viruses after 96 h, although a trend towards higher growth for
later passages was seen (Fig. 1A). No differences in growth
curves were observed as measured by sequential reciprocal
HA titers (Fig. 1B). Peak reciprocal HA titers were 256 to 512
for all viruses.
Morbidity and mortality of mouse-adapted intermediates in
mice
Groups of 6 mice were administered 1  106 TCID50 of
each of the 5 viruses intranasally and followed daily for
weight loss. All mice were infected and exhibited clinical
signs of influenza including decreased activity, huddling,
hunched posture, and ruffled fur. Mice in the M0, M3, M6,
and M9 groups could not be distinguished by visual
inspection and recovered clinically after 2–3 days and
resumed their normal activity. Mice in the MA group,
however, grew progressively more ill with worsening clinical
signs including labored breathing and tail cyanosis over the
first 14 days before recovering slowly over an additional 7–
10 days. Weight loss reflected this difference in morbidity
between theMAgroup and the other 4 groups (Fig. 2A).Mice
in theMA group lost weight progressively over the first 7–10
days and did not begin to recover until approximately 14 days
post-infection. Mortality could not be observed at any dose ofthe M0, M3, M6, and M9 viruses (up to a maximum dose of
1  107 TCID50), while the MLD50 of the MA virus was
determined to be approximately 3  106 TCID50 and the
virus was 100% lethal at a dose of 1  10 7 TCID50. The
virus had similar virulence in C57Bl/6 mice (data not
shown). These results indicate that changes which occurred
between the 9th and 15th passages conferred virulence and
lethality on the virus.
Viral growth in mouse lungs
Groups of 6 mice were infected with 1  106 TCID50 of
each of the 5 viruses. Three mice from each group were
sacrificed on days 3 and 7 post-infection (p.i.) and viral titers
were determined from their lungs. Virus could be recovered
from the lungs of all mice at day 3 p.i., and viral titers were
sigsnificantly higher in the MA-infected group than in the
Fig. 2. Virulence of mouse-adapted intermediates in mice. Groups of 6 mice
were infected with parental virus (M0), 3rd (M3), 6th (M6), 9th (M9), and
15th (MA, mouse adapted) passages and followed daily for weight loss (A)
as a measure of morbidity. Mice infected with the MAvirus lost significantly
more weight than mice infected with other viruses. Mice infected with the
MAvirus also had significantly higher viral lung titers (B) both 3 days and 7
days after viral infection. An asterisk (*) indicates a statistically significant
difference compared to the other groups while a double asterisk (**)
indicates a significant difference compared to only the M0, M3, and M6
groups ( P < 0.05).
Table 1
Nucleotide and amino acid changes in wild-type and mouse-adapted
influenza virus B/Memphis/12/97
Viral proteins Changed nucleotidesa Changed amino acidsb
PB1 1241 (G to A) 
1529 (T to C) 
1877 (C to T) 
PB2 1655 (G to A) 
PA 756 (C to T) 
917 (G to A) 
977 (A to T) 
1264 (C to A) Thr to Asn (412)
1553 (A to G) 
1766 (G to A) 
1796 (G to A) 
1835 (T to C) 
HA 480 (T to C) 
603 (G to A) 
664 (A to G) Asn to Asp (223)
1218 (G to A) 
1354 (C to T) 
1362 (A to G) 
NP 219 (G to A) 
1255 (T to C) 
1595 (G to A) Ser to Asn (513)
NA/NBc 89 (C to T) Pro to Ser (NB 15)
216 (A to G) Tyr to Cys (NB 57)
Thr to Ala (NA 55)
569 (T to C) 
1022 (G to A) 
1429 (T to C) Val to Ala (NA 459)
M1/BM2d 270 (C to T) 
686 (A to G) Asn to Ser (M1 221)
758 (A to G) 
NS 126 (C to T) 
a Numbering of nucleotides is relative to B/Lee/40 beginning at the start of
the non-coding region of the RNA segment.
b Numbering of amino acids is relative to B/Lee/40 beginning at the start of
the coding region.
c RNA segment 6 contains overlapping reading frames coding for the
neuraminidase (NA) and the NB protein.
d RNA segment 7 encodes two polypeptides, M1 and BM2, using tandem
cistrons.
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day 7 p.i. from all the lungs of MA-infected mice at titers
similar to those seen at day 3 p.i., while virus could only be
recovered sporadically and at low titers from the other 4
groups at day 7 p.i. Virus could not be recovered from brain or
blood at any dose of the MAvirus (data not shown). Thus, the
MA virus is better adapted to mouse lungs as evidenced by
improved growth both at peak (day 3 p.i.) and late in infection
(day 7 p.i.), although differences in peak viral titer between
the M9 and M15 viruses were only seen at 7 days. These data
suggest that the failure to clear the virus from the lungs is
responsible for the increased virulence and lethality observed
with the MA virus.
Differences in nucleotide and deduced amino acid
sequences of the parent and MA viruses
The coding regions of all 10 genes of the M0 and MA
viruses were sequenced and compared. Thirty nucleotidechanges resulted in 8 deduced amino acid differences in
5 of the 8 gene segments and 6 of the 10 genes of
influenza B virus (Table 1). Two of the deduced amino
acid changes occurred as a result of 1 nucleotide change
in gene segment 6 which contains overlapping reading
frames coding for the neuraminidase (NA) and the NB
proteins. Thus 7/30 (23%) nucleotide changes resulted in
deduced changes in amino acids. This is in contrast to
data from the mouse adaptation of an influenza A virus,
where 11/15 (73%) of nucleotide changes resulted in amino
acid changes (Brown et al., 2001).
Two deduced amino acid changes were present in the
NA and the NB and 1 change was present in each of the
PA, HA, NP, and M1. No deduced amino acid changes
were present in the PB1, PB2, BM2, NS1, or NS2. The
amino acid changes Thr412Asn in the PA, Val459Ala in
the NA, and Asn221Ser in the M1 are unique at their
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in the Influenza Sequence Database (ISD) (Macken et al.,
2001). The remaining 5 deduced amino acid changes
were at positions where variation is present in sequences
in the ISD and were not unique. The change at
nucleotide position 664 of the HA (A to G) leading to
deduced amino acid change Asn223Asp was not constant;
electrophoretic peaks for both an A and a G could be
seen at that position during sequencing of the M3 and
M6 intermediates, although the G predominated after the
9th passage. Similarly, both A and G were seen variably
in the M3, M6, and MA intermediates at position 758 of
gene segment 7 which could potentially lead to an amino
acid change Lys245Arg. However, the A at that position
predominated as the major electrophoretic peak and was
most reliably present in all viruses with repeated
sequencing so no change from the conserved Lys at that
position is reported. Sequencing results are from the same
plaque purified virus stock as the in vivo experiments.
Order of deduced amino acid changes during passaging in
mice
Partial sequencing of the M3, M6, and M9 viruses
was done including all positions where there were
differences between the parent and the MA virus. Four
deduced amino acid changes were present by the third
passage (Table 2). All of these early differences were
changes to non-unique amino acids at non-conserved
positions, three of them within the portion of gene
segment 6 containing the overlapping reading frames for
NA and NB. Two changes occurred between the 3rd and
6th passages, and 1 change each between the 6th and 9th
and the 9th and 15th passages. Three of the latter 4
changes were to amino acids unique for that position at
positions that are otherwise conserved among influenza B
viruses. The exception was the difference in the HA
which was seen variably in intermediate passages. It is
unclear from this analysis which of these changesTable 2
Sequence of amino acid changes during mouse adaptation
Viral proteins
(amino acid)
M0 M3 M6 M9 MA
NP (513) Ser Asna Asn Asn Asn
NB (15) Pro Ser Ser Ser Ser
NA (55) Thr Ala Ala Ala Ala
NB (57) Tyr Cys Cys Cys Cys
PA (412) Thr Thr Asn Asn Asn
NA (459) Val Val Ala Ala Ala
HA (223) Asn Asn Asn Asp Asp
M1 (221) Asn Asn Asn Asn Ser
Note. M0, parent virus Mem97; M3, 3rd mouse passage; M6, 6th mouse
passage; M9, 9th mouse passage; MA, mouse-adapted virus after 15
passages.
a Boldface is used to emphasize the passage at which changes were first
observed.contribute to adaptation of the virus to mouse lungs.
However, the increase in virulence and failure to clear the
virus from mouse lungs seen between the 9th and 15th
passages can be attributed to a single amino acid change,
asparagine to serine at position 221 of the M1.
A serine at position 221 of the M1 confers mouse adaptation
and virulence
Although it was evident that the Asn221Ser change in
the M1 protein was necessary for expression of virulence,
two questions remained. It was not clear whether other
changes that occurred earlier in the adaptation process
also contributed to adaptation and were therefore neces-
sary for expression of virulence with the change in the
M1, and it was not known whether an M1 containing
this change could confer adaptation and/or virulence in a
different background, i.e., another influenza B virus.
Therefore we utilized the eight plasmid reverse genetics
system (Hoffmann et al., 2002) for influenza B viruses to
transfer the M gene segment of the Mem97-MA virus
containing the serine at position 221 to a different virus,
B/Yamanashi/166/98 (Yam98) creating a 1:7 reassortant
(rgYam98-M (Mem97MA)). Besides the amino acid of
interest at 221, the viruses differ in the M1 at position 97
(threonine in Yam98 and isoleucine in Mem97), in the
BM2 at position 82 (asparagine in Yam98 and serine in
Mem97), and at 9 other amino acid positions scattered
throughout the genome. Therefore we also mutated the
Yam98 M1, changing the asparagine at position 221 to a
serine so the new virus (rgYam98-M1 (N221S)) could be
compared to an otherwise isogenic wild-type parent
(rgYam98). The peak HA titers (256–512 HA units)
and TCID50s of the stocks (1  107–1  107.5) did not
differ significantly among the 3 viruses.
The wild-type virus, rgYam98, was found to be
avirulent in mice with an MLD50 of greater than 10
7
TCID50. To evaluate any difference in virulence caused
by changes in the M segment, groups of 6–8 mice were
given 1  106 TCID50 of either rgYam98, rgYam98-M
(Mem97MA), or rgYam98-M1 (N221S) and followed for
weight loss and mortality. Infection with rgYam98
resulted in no weight loss, no clinical signs of infection,
and no deaths. However, infection with rgYam98-M
(Mem97MA) and rgYam98-M1 (N221S) caused typical
clinical symptoms of influenza infection, severe weight
loss (Fig. 3A), and 100% mortality (Fig. 3B). In a
separate experiment, groups of 8 mice were infected with
2  105 TCID50 of each virus for determination of lung
titers (the lower dose was used so mice would survive
until day 7). Lung titers at day 3 and day 7 were higher
in mice infected with rgYam98-M (Mem97MA) and
significantly higher in mice infected with rgYam98-M1
(N221S) (Fig. 3C); virus was completely cleared from
mice infected with rgYam98 by day 7. These experiments
establish that adaptation and virulence can be conferred
Fig. 3. A serine at position 221 of the M1 confers mouse adaptation and
virulence. Reassortant viruses containing either 7 genes from Yam98 but
the M segment of Mem1297-MA, or a mutated M1 gene with the N221S
change, caused more weight loss (A), high mortality (B), and higher viral
titers (C) at day 3 and day 7 after infection. An asterisk (*) indicates a
statistically significant difference compared to the wild-type virus rgYam98
(P < 0.05).
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segment from the MA virus using reverse genetics.Discussion
Adaptation can be described as the modification of an
organism or its parts that makes it more fit for existence
under the conditions of its environment. Adaptation can
manifest as infection of an increased number or range of
cell types (tissue tropism), an increase in susceptibility inhosts of different ages (host range), or as the ability to
induce pathology (Ward, 1997). Virulence is more difficult
to define but is linked to the ability of an organism to
cause disease in its host; as relative virulence increases so
does the severity of disease and the likelihood of death.
Most modern influenza B virus strains will grow without
adaptation to low titers in mouse lungs but are avirulent
(personal observation, author J.A.M.). In the mouse-
adapted variant we describe here, it is uncertain which,
if any, of the 7 deduced amino acid changes seen prior to
the change in the M1 can contribute to adaptation or
support virulence, since no change in phenotype was seen
during the first 9 passages (Figs. 1 and 2), and only the
contribution of the M gene segment was examined using
reverse genetics.
During the first 3 passages, all 4 of the predicted amino
acid changes (Table 2) occurred at sites which were neither
unique nor conserved, 3 of them in the stretch of
nucleotides coding for both the cytoplasmic portion of
the NB protein and the hypervariable stalk region of the
NA (Burmeister et al., 1993). In all 4 instances the change
was from a less common variant in the parent to a more
common variant in the MA virus (data not shown). For
these reasons they are less likely to be involved in
adaptation than later changes which result in unique amino
acids at conserved sites. Two further deduced amino acid
changes occurred between the 3rd and 6th passages,
Thr412Asn in the PA and Val459Ala in the NA. The
amino acid change Val459Ala is in the highly conserved
C-terminal region of the NA head distal to the 6th beta-
strand (Burmeister et al., 1992). Although not a part of the
enzyme active site, a mouse-adapted influenza A virus also
has a mutation in the corresponding region implying a
potential role in growth or adaptation (Brown et al., 2001).
Changes at amino acids 458 and 463 of the NA in a
temperature-sensitive influenza B virus mutant have been
implicated in assembly and growth defects at the non-
permissive temperature (Miyazaki et al., 1993). Therefore,
changes in this area of the NA could potentially affect
replication and growth, and could contribute to adaptation
either independently or in concert with the change in M1.
The MA virus on the Mem97 background with these
changes was not evaluated head to head with the
rgYam98-M (Mem97MA) virus that lacked these changes,
so no conclusions can be drawn at this point.
Many earlier publications focused on the role of the HA
and the M1 proteins in adaptation to mouse lungs (Brown,
1990; Frosner and Gerth, 1973; Gitelman et al., 1984;
Govorkova et al., 2000; Hartley et al., 1997; Kaverin et al.,
1989; Rudneva et al., 1986; Smeenk and Brown, 1994;
Smeenk et al., 1996; Smirnov et al., 2000; Ward, 1995). We
identified a change in the HA between the 6th and 9th
passages, but it was only variably present in the quasi-
species pool of viruses and did not result in any change in
virulence. The change in the M1, however, is clearly related
to virulence. An examination of previously published work
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2000; Lee et al., 2001) and of the M1 sequences in the
Influenza Sequence Database (Macken et al., 2001) shows
that many mouse-adapted influenza viruses have unique
changes in a short stretch of the C-terminal domain (C) of the
M1 protein (Fig. 4). The predicted amino acid change
Lys245Arg seen in B/Lee/40 was also present variably in
intermediates during passaging of Mem97 but was not the
predominant residue at any point. Variations in the N-
terminal (N) and middle (M) domains of the M1 have also
been associated with virulence in mouse lungs, albeit less
frequently (Brown, 1990; Brown and Bailly, 1999; Lee et al.,
2001; Ward, 1997).
The M1 protein is involved during multiple steps of
replication with roles in assembly and budding (Bui et al.,
1996; Liu et al., 2002; Ye et al., 1999). Functional and
structural studies have localized RNA and RNP binding to
the M and N domains, but little is known about the C domain
(Liu and Ye, 2002; Sha and Luo, 1997; Ye et al., 1987,
1999). The C domain, which is not visualized by X-ray
crystallography, may either hang into the virion’s interior
(Sha and Luo, 1997) or may be membrane embedded
(Shishkov et al., 1999). Functionally, it may interact with
the RNP or with an unidentified host protein (Sha and Luo,
1997). Although there is significant sequence homology
between influenza viruses in the N and M domains of M1,
little is seen in the C domain where the majority of changes
in mouse-adapted viruses are found (Briedis et al., 1982).
Our data suggest that this region of the M1 contributes to
growth and virulence in mouse lungs although identification
of the mechanism awaits further study.
We have mouse adapted an influenza B virus representa-
tive of currently circulating strains until it was lethal. Transfer
of the M gene segment of this virus to another virus or site-
directed mutagenesis of the M segment of the second virus
conferred mouse adaptation and virulence. Knowledge that
this change can confer virulence should allow us to rapidly
adapt influenza B viruses using reverse genetics. Use of anMFig. 4. Unique amino acids found in the C region of the M1 protein associated w
arrowhead indicates the position of the amino acid change M1 N221S reported her
in this region in other mouse-adapted influenza viruses. The N and M domains are s
in influenza A viruses (252 amino acids) compared to influenza B viruses (248 asegment containing a serine at position 221 during con-
struction of viruses by reverse genetics should allow study of
the role of unrelated genes such as the HA or NA in mouse
models of vaccine efficacy or drug treatment.Materials and methods
Infectious model
Six- to eight-week-old female Balb/cByJ mice (Jackson
Laboratory, Bar Harbor, ME) were maintained in a
Biosafety Level 2 facility in the Animal Resource Center
at St. Jude Children’s Research Hospital. Influenza virus
was diluted in sterile PBS and administered intranasally in a
volume of 100 Al (50 Al per nostril) to anesthetized mice
held in an upright position. Mice were weighed and
followed at least daily for illness and mortality. Mice found
to be moribund were euthanized and considered to have
died on that day. Anesthetized mice were euthanized by
cervical dislocation or CO2 inhalation. Lungs were remov-
ed under sterile conditions, washed three times in sterile
PBS, and placed into 500 Al of sterile PBS. Lung
homogenates were spun at 10,000  g for 5 min and the
supernatants used for determination of viral titers. Viral
titers were determined by 10-fold serial dilutions on MDCK
cell monolayers to obtain the dose infectious for 50% of
tissue culture wells (TCID50). All experimental procedures
involving mice were approved by the Animal Care and Use
Committee at St. Jude Children’s Research Hospital and
were done under general anesthesia with inhaled isoflurane
2.5% (Baxter Healthcare Corporation, Deerfield, IL).
Adaptation of B/Memphis/12/97 to mouse lungs
Influenza virus B/Memphis/12/97 (McCullers et al.,
1999a, 1999b) was obtained from the virus repository at
St. Jude Children’s Research Center and passaged in mice.ith mouse adaptation of influenza A and B viruses. The broad down-going
e, while narrow up-going arrowheads indicate the positions of changes seen
haded. The dotted line indicates the slightly greater length of the M1 protein
mino acids). NLS = nuclear localization signal.
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a 1:100 dilution of viral stock (approximately 103 to 104
TCID50 of virus per mouse depending on the passage) and
euthanized 72 h later to recover virus from the lungs. Virus
was amplified once for stock in MDCK cells in the
presence of 0.1% trypsin-TPCK (Worthington Biochemical
Corporation, Lakewood, NJ) before being put back into
mice at each passage by blindly passaging a 1:1000
dilution of lung homogenate on MDCK cells for 96 h. The
lung homogenates were titered simultaneously on a
separate tissue culture plate. This allowed determination
of viral titers and preservation of stock virus for further
studies, as well as insuring sufficient virus was present to
allow for selection. Virus was passaged through lungs 15
times before sequencing and pathogenicity studies were
begun. The parent virus (M0), 3 intermediate passages
(M3, M6, and M9), and the 15th passage (MA) were
plaque purified in MDCK cells. Working stocks were then
made by growing virus at a multiplicity of infection of 0.1
for 96 h at 33- so that each intermediate was uniformly
prepared. These working stocks were used for all experi-
ments. HA titers were determined by standard methods.
Briefly, twofold dilutions of virus containing supernatant
from MDCK cells were exposed to 0.5% chicken red blood
cells and allowed to incubate for 30 min at room
temperature. The titer was read as the furthest dilution
where hemagglutination by binding of the virus and cross-
linking prevented pelleting of red blood cells in U-
bottomed 96-well plates and was reported as the reciprocal
log2.
Sequencing and GenBank accession numbers
Nucleotide sequencing was done using standard metho-
dologies as described (McCullers et al., 1999a, 1999b).
Briefly, RNA was transcribed to cDNA by using Uni12-
primer (AGC AAA AGC AGG) and the cDNA was then
amplified using segment-specific primers. RT-PCR products
were purified using QIAquick PCR purification kit (Qiagen,
Chatsford, California) and sequenced by Taq Dye Termi-
nator chemistry according to manufacturer’s instructions
(Applied Biosystems, Inc.), then analyzed on an ABI 373
DNA sequencer. The open reading frames of all 10 genes of
the eight gene segments of the M0 and the MA viruses were
completely sequenced. Portions of the intermediates M3,
M6, and M9 were sequenced including all areas where any
differences were noted between the parent and the MAvirus.
Comparisons of nucleotide and amino acid sequences were
facilitated by use of the Influenza Sequence Databank (ISD)
(Macken et al., 2001). Sequences for B/Memphis/12/97 have
been previously reported (McCullers et al., 2004), and
sequences of B/Memphis/12/97-MA are available in the ISD
or in GenBank with the following accession numbers: PB1
(AY260949), PB2 (AY260950), PA (AY260951), HA
(AY260952), NP (AY260953), NA (AY260954), M (AY2
60955), and NS (AY260956).Generation by reverse genetics of a reassortant virus
containing the mouse-adapted M1
Viral RNA from the Mem97-MA virus was reverse
transcribed and amplified by PCR using segment-specific
primers for the M segment (segment 7), MDV-B 5V Bsa1-M
(TATTGGTCTCAGGGAGCAGAAGCACGCACTTTCT-
TAAAATG) andMDV-B 3VBsa1-M (ATATGGTCTCGTAT-
TAGTAGAAACAACGCACTTTTTCCAG). This primer
pair was based on the primer set used for rescue of an
influenza B virus from cloned cDNA plasmids as previously
described (Hoffmann et al., 2002) but has recognition sites for
the endonuclease Bsa1 (GGTCTC) instead of for that of
BsmB1 (CGTCTC), as the latter sequence is present in gene
segment 7 and would have created multiple fragments during
digestion. The resulting RT-PCR fragment was isolated,
digested with Bsa1, and inserted into the BsmB1-digested
plasmid pHW2000 (Hoffmann et al., 2000). The open reading
frame and viral non-coding regions of the resulting plasmid
were directly sequenced and were found to be identical to the
sequences of the open reading frame of the M segment of the
MA virus and the consensus viral non-coding regions of this
influenza B virus segment (Hoffmann et al., 2002).
The protocol used for rescue of the reassortant influenza
B virus was based on the protocol for generation of in-
fluenza A virus (Hoffmann et al., 2000). Briefly, 293T cells
were transiently co-cultured with MDCK cells in six-well
plates. Two micrograms of the newly generated plasmid
containing the M segment of the MA virus and 2 Ag each
of plasmids for the PB1 (pAB251-PB1), PB2 (pAB252-
PB2), PA (pAB253-PA), HA (pAB254-HA), NP (pAB255-
NP), NA (pAB256-NA), and NS (pAB258-NS) of
influenza virus B/Yamanashi/166/98 obtained from MedI-
mmune, Inc. (Gaithersburg, MD), were mixed with 2 Al of
TransIT-LT-1 (Mirrus, Madison, WI) per 1 Ag of plasmid
DNA, incubated at room temperature for 45 min, and
added to the cells. After 6 h, the DNA-transfection mixture
was replaced by Opti-MEM I (Life Technologies, Rock-
ville, MD). The cells were incubated at 33 -C. Fresh media
containing 0.1% trypsin-TPCK (Worthington Biochemical
Corporation, Lakewood, NJ) was added 24 h later and
virus was harvested at 96 h and passaged on MDCK cells
for stock. The resultant stock was titered on MDCK cells
to obtain the TCID50, and the M1 open reading frame was
sequenced to confirm that the mutation of interest resulting
in a serine at position 221 was present. Limited sequencing
of other gene segments including the HA and NA
confirmed that the other gene segments were derived from
B/Yamanashi/166/98.
Site-directed mutagenesis of the M segment of
B/Yamanashi/166/98
TheM1 region of the M gene of B/Yamanashi/166/98 was
specifically mutated such that the asparagine at position 221
became a serine, using primers (For 5V -CTTGGAGCAAGT
J.A. McCullers et al. / Virology 336 (2005) 318–326 325CAA AAG AGC GGG GAA GGA ATT GCA AAG-3V , Rev
5V CTT TGC AAT TCC TTC CCC GCT CTT TTG ACT
TGC TCC AAG-3V ) that were synthesized at the Hartwell
Center (St. Jude Children’s Research Hospital). Site-directed
mutagenesis was performed on 25 ng of plasmid DNA using
the QuikChange II site-directed mutagenesis kit from
Stratagene (Stratagene, La Jolla, CA). After 16 cycles in a
DNA Engine DYAD Peltier Thermal Cycler (MJ Research,
Inc., Waltham, MA), parental DNA was digested using the
restriction enzyme DpnI (Strategene), and chemically com-
petent DH5-a Escherichia coli (Invitrogen, Carlsbad, CA)
cells were transformed with the mutated plasmid DNA.
Plasmids obtained from colonies grown on LB (Q-Biogene,
Irvine, CA) with 100 Ag mL1 Ampicillin (Sigma, St. Louis,
MO) were sequenced, and colonies with the single N221S
mutations were maxi-prepped using a Hi-Speed Plasmid
Maxi Kit (Qiagen, Valencia, CA). The 8-plasmid reverse
genetics system (Hoffman et al.) was utilized, and a B/
Yamanashi/166/98 virus clone containing a single mutation
in the M1 region of its M gene (N221S) was rescued from
MDCK cells. Viral RNA isolated using the RNeasy RNA
extraction kit (Qiagen) was amplified using the One-Step RT-
PCR Kit (Qiagen) with matrix-specific primers. Products
were purified using the QIAquick PCR Purification Kit
(Qiagen) and sequenced with matrix-specific primers to
confirm the presence of the N221S mutation.
Statistical analyses
Comparison of survival between groups of mice was
done with the Mantel-Cox chi-squared test on the Kaplan–
Meier survival data. Comparison of viral titers in lungs
between groups was done with the Wilcoxon rank sum test.
Comparisons of weight loss between groups were done
using the Student’s t test for pairwise comparisons and one
way analysis of variance (ANOVA) followed by Dunn’s
test for comparisons among multiple groups. A P value of
<0.05 was considered significant for these comparisons.Acknowledgments
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